Ubs Group Ag Pacira Bio Sciences, Inc. Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,028,889 shares of PCRX stock, worth $24.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,028,889
Previous 421,832
143.91%
Holding current value
$24.3 Million
Previous $10.5 Million
134.59%
% of portfolio
0.0%
Previous 0.0%
Shares
34 transactions
Others Institutions Holding PCRX
# of Institutions
257Shares Held
51.2MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$189 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$128 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$56.6 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$53.2 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$50.8 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.08B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...